FDA Feedback on BB-301 Pivotal Design Adds Clarity; Enrollment Still on Track for Mid-2027
BNTC is trading near its 52-week low of $8.92 (0.0% above the low).
Summary
Benitec received formal FDA feedback on its BB-301 pivotal study design, with the agency requesting additional natural history data. Final design confirmation is now expected in 1Q 2027, with enrollment still planned for mid-2027. Interim Phase 1b/2a data will be presented at ESGCT in late October.
Key Events · Product Development and Regulatory · BNTC
-
FDA Requests Additional Natural History Data
Following the Type C meeting, the FDA requested additional available data, including from the Benitec-sponsored OPMD Natural History Study, to inform the pivotal study design for BB-301.
-
Pivotal Study Design Confirmation Delayed to 1Q 2027
Final pivotal study design is now expected to be confirmed in 1Q 2027, with patient enrollment still planned to begin in mid-2027.
-
ESGCT Presentation to Include 12-Month Cohort 1 Data
Benitec will present interim clinical results as a late-breaking poster at ESGCT on October 27-30, 2026, including 12-month follow-up data for all six Cohort 1 patients and interim data for all three Cohort 2 patients.
-
BB-301 Remains on Track for Mid-2027 Pivotal Start
Despite the additional data request, the company states timelines for the BB-301 pivotal study remain on track, with enrollment planned to begin in mid-2027.
Analysis · BNTC · Life Sciences
The FDA's formal feedback following the Type C meeting brings new regulatory clarity for BB-301. The agency requested additional data from the OPMD Natural History Study, which pushes final pivotal study design confirmation to 1Q 2027. While the timeline remains on track for mid-2027 enrollment, the request introduces a modest delay in finalizing the study design. The upcoming ESGCT presentation on October 27-30 will provide the first look at 12-month Cohort 1 data and interim Cohort 2 data, a key clinical readout for investors.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTC was trading at $8.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $313.2M. The 52-week trading range was $8.92 to $16.76. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.